GlassScriptPhysician profile
Julie B Greenberg
NPI 1558382382
$2,615.71
in general payments reported to CMS, 2019-2025
21 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $200 · 2021: $366 · 2022: $420 · 2023: $626 · 2024: $396 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $365.04 | 2020-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $333.39 | 2019-2024 | Cequa |
| Alcon Vision LLC | $290.07 | 2019-2025 | Total30, Tryptyr, Precision7 |
| Oyster Point Pharma, INC. | $212.31 | 2022-2024 | Tyrvaya |
| Abb Con-Cise Optical Group LLC | $199.80 | 2019-2024 | Spectacle Lenses, Contact Lens |
| Regeneron Healthcare Solutions, INC. | $196.11 | 2021-2025 | Eylea |
| Tarsus Pharmaceuticals, INC. | $185.65 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $174.09 | 2021-2024 | Oxervate |
| Allergan, INC. | $139.20 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $84.74 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.40 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $82.03 | 2022-2025 | Infuse, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $78.15 | 2019-2023 | |
| Abbvie INC. | $56.61 | 2022-2024 | |
| Eyevance Pharmaceuticals LLC | $41.61 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $17.09 | 2020 | |
| Apellis Pharmaceuticals, INC. | $17.01 | 2025 | Syfovre |
| Maculogix, INC. | $15.82 | 2019 | |
| Kala Pharmaceuticals, INC. | $15.20 | 2021 | |
| Shire North American Group INC | $14.24 | 2019 | |
| Harrow Eye, LLC | $13.15 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.